33
Participants
Start Date
November 13, 2014
Primary Completion Date
August 20, 2019
Study Completion Date
August 20, 2019
rFIXFc
Adjustments to the dose and interval of rFIXFc was made in this study based on investigator discretion using available pharmacokinetic (PK) data, subsequent FIX trough and peak levels, level of physical activity, and bleeding pattern, in accordance with local standards of care for a prophylactic regimen. There was an option to start study dosing as episodic treatment (on-demand).
Research Site, Auckland
Research Site, Westmead
Research Site, Aarhus
Research Site, Pittsburgh
Research Site, Washington D.C.
Research Site, Milan
Research Site, Atlanta
Research Site, Louisville
Research Site, Parma
Research Site, Columbus
Research Site, Indianapolis
Research Site, East Lansing
Research Site, Traverse City
Hopital Cardiologique - CHU Lille, Lille
Research Site, Lyon
Research Site, New Orleans
Research Site, Napoli
Research Site, Sacramento
Research Site, Portland
Research Site, Dublin
Research Site, Roma
Research Site, Utrecht
Research Site, Warsaw
Research Site, Malmo
Research Site, Cambridge
Research Site, Whitechapel
Research Site, London
Collaborators (1)
Swedish Orphan Biovitrum
INDUSTRY
Bioverativ, a Sanofi company
INDUSTRY